-
Product Insights
Open-Angle Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Open-Angle Glaucoma - Drugs In Development, 2023’, provides an overview of the Open-Angle Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non-infectious Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-infectious Uveitis - Drugs In Development, 2023’, provides an overview of the Non-infectious Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-infectious Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveitis - Drugs In Development, 2023’, provides an overview of the Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2023’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PM-1015 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PM-1015 in Solid Tumor Drug Details: PM-1015 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Veliparib ER in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Veliparib ER in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Veliparib ER in Head And Neck...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Remternetug in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remternetug in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remternetug in Alzheimer's Disease Drug Details: Remternetug (LY-3372993) is under development for...